ReviewBlockade of the renin–angiotensin–aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: A systematic review and meta analysis of randomized controlled trials
Introduction
Atrial fibrillation is the most common type of arrhythmia and is associated with an increased risk of stroke, heart failure and death [1]. The renin–angiotensin–aldosterone system (RAAS) is suggested to play a key role in the development of atrial fibrillation through structural and electrical remodeling but the exact mechanism remains unclear [2].
A number of trials investigated the effectiveness of angiontensin-converting enzyme inhibitors (ACEIs) [4,13], angiotensin-II receptor blockers (ARBs) [12], and aldosterone antagonists [5,9] in reducing atrial fibrillation with inconsistent results. Clinical guidelines described the potential role of RAAS blockade for the reduction of atrial fibrillation recurrence but provide no specific class recommendations. Further, no recommendation is provided regarding the prevention of new onset atrial fibrillation in different cardiovascular disease patients at high risk. A number of meta-analyses were conducted on this topic as this area is continuously evolving and evidence is being updated accordingly [2], [6], [3]. These reviews indicated statistically significant reduction in the rate of atrial fibrillation among patients with heart failure [2], [6], [3]. None of the reviews focused on new onset atrial fibrillation and it was not clear if ACE inhibitors and ARBs had different effects on the prevention of new onset atrial fibrillation [6]. Further, previously published reviews did not include trials that used aldosterone antagonists.
The objective of this meta-analysis is to investigate ACEIs, ARBs, or aldosterone antagonists compared with conventional therapy or placebo on the prevention of new-onset atrial fibrillation. In addition to examining the overall results, this review also explored the impact of RAAS inhibition across different patient populations (heart failure, myocardial infarction, coronary artery disease/ cardiovascular risk factors) and drug classes (ACEIs, ARBs and aldosterone antagonists).
Section snippets
Search strategy
Methods of the analysis and inclusion criteria were specified in advance and documented in a published protocol in the International Prospective Register of Systematic Reviews (PROSPERO), registration number CRD42011001125 (http://www.crd.york.ac.uk/prospero/).
The following bibliographic databases were searched through Ovid interface: MEDLINE (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1948 to January 2011), EMBASE (from 1948 to January 2011), and The Cochrane
Study selection
A total of 14 trials were identified for inclusion in the review, 3 of which have not been included in previous meta-analyses [2], [3], [6]. The search of Medline, Embase, and CENTRAL databases provided a total of 3861 citations. Two more citations were added through content experts and going through ACC meeting abstracts. After adjusting for duplicates 3593 trials remained. Of these, 3531 studies were discarded because after reviewing the titles and/or abstracts these papers clearly did not
Summary of results
The pooled estimate indicated an overall 21% reduction of new onset atrial fibrillation due to RAAS inhibition. Two previous meta-analyses presented results separately for new onset atrial fibrillation [6]. The current Meta-analyses included 3 more trials [17], [16], and showed similar overall reduction in atrial fibrillation. It is important to note that of these three new trials included in this systematic review, one included only 91 patients [17] and the other two had relatively short
Conclusions
The majority of the patient population included in these trials is already on anti hypertensive medication, most of which take ACE inhibitors or ARBs. Results from this review suggest an added benefit to these drug classes in addition to aldosterone antagonists in the prevention of atrial fibrillation. Patients with heart failure are most likely to benefit from these medications. Due to the low quality of evidence these results should be taken with caution until stronger evidence is generated.
Conflict of interest statement
None declared.
Acknowledgements
The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology.
References (20)
- et al.
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis
J Am Coll Cardiol
(Jun 7 2005) - et al.
Angiotensin II Receptor Blockade Reduces New-Onset Atrial Fibrillation and Subsequent Stroke Compared to Atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
J Am Coll Cardiol
(2005) - et al.
Eplerenone and atrial fibrillation in mild systolic heart failure – results from the eplerenone in mild patients hospitalization and SurvIval study in heart failure (EMPHASIS-HF) study
J Am Coll Cardiol
(2012 May 1) - et al.
Prevention of atrial fibrillation by renin–angiotensin system inhibition a meta-analysis
J Am Coll Cardiol
(May 25 2010) - et al.
Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure
J Card Fail
(Apr 2007) - et al.
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial
Lancet
(Feb 20 1999) - et al.
Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 Study
Lancet
(1999) - et al.
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the valsartan heart failure trial (val-HeFT)
Am Heart J
(Mar 2005) - et al.
Impact of ramipril on the incidence of atrial fibrillation: results of the heart outcomes prevention evaluation study
Am Heart J
(Sep 2007) - et al.
Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis
Am J Cardiol
(Sep 1 2010)
Cited by (98)
Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study
2022, Journal of the American College of CardiologyApplying cooperative module pair analysis to uncover compatibility mechanism of Fangjis: An example of Wenxin Keli decoction
2021, Journal of EthnopharmacologyCitation Excerpt :It is reported that the neurohumoral dysfunction is a core contributor to SAF as well as subsequent structural remodeling [Yongjun et al., 2015]. AHA 2014 guidelines advocated the renin-angiotension-aldosterone (RAAS) blockade for primary prevention of atrial AF [Rasha et al., 2013; January et al., 2014]. Our results also suggested that WXKL could regulate steroid hormone secretion and renal sodium extraction.
Prevention of Pathological Atrial Remodeling and Atrial Fibrillation: JACC State-of-the-Art Review
2021, Journal of the American College of CardiologyFrequency of Atrial Arrhythmia in Hospitalized Patients With COVID-19
2021, American Journal of CardiologyHypertension, Prehypertension, Hypertensive Heart Disease, and Atrial Fibrillation
2021, Cardiac Electrophysiology Clinics